Skip to content
Back to SRPT

Sarepta Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
2
Purchases
0
Sales
2
Purchase value
$0.00
Sale value
$417.41K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Stephen MayoDirector
4
Filed Mar 13, 2026Period of report Mar 12, 20260001193125-26-106701
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 12, 2026
Common StockF17,239$17.02$123.21K1,765Direct
Filing footnotes · 1
  1. F1Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.
Open on SEC EDGAR
Ian Michael EstepanChief Operating Officer
4
Filed Dec 18, 2025Period of report Dec 16, 20250001193125-25-325383
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF1F213,187$22.31$294.20K193,300Direct
Filing footnotes · 2
  1. F1Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.35 to 22.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.